Losing 20 or 30% of your body weight changes what you are worried about.
The questions shift. What came off with the fat. What to do about the skin. Why your hair is thinning. Whether any of it comes back.
A market has grown to meet those questions. One of them has a real answer with evidence behind it, and the rest mostly do not.
Does semaglutide cause muscle loss?
Yes, and how much is genuinely disputed. Of everything on this page, it is the concern with real substance behind it.
In the STEP 1 body composition substudy, participants on semaglutide lost around 6.9 kg of lean soft tissue alongside 10.4 kg of fat. Depending on which analysis you read, lean tissue accounted for somewhere between 30% and 40% of total weight lost.[^1]
That sounds alarming. Two pieces of context change how it reads.
Some lean loss is normal in any weight loss
Losing fat means losing the tissue that supported it, and the proportion in these trials is broadly comparable to what happens with diet-driven weight loss. The trials also found the proportion of lean mass relative to total body mass increased, because fat came off faster.
Function held up
The STEP 1 analyses found no consistent clinically meaningful declines in physical function.[^1]
And a 2026 study found something more encouraging. In 106 patients on semaglutide, lean mass fell by about 3 kg at seven months and then stabilised. Handgrip strength improved by 4.5 kg at twelve months, and the prevalence of sarcopenic obesity fell from 49% to 33%.[^2]
So people got stronger while their lean mass went down. Those are different measurements and only one of them is what you actually care about.
Can you prevent muscle loss on a GLP-1?
A case series followed people who preserved or increased lean soft tissue during treatment. One lost 8.7% of weight as lean tissue, which is well below the trial average. Two increased theirs.[^3]
The authors hypothesise that consistent exercise and resistance training explain it, and they are careful to say it is a hypothesis from three cases.
That is thin evidence and it points the same way as everything else known about preserving muscle during weight loss. Resistance training and adequate protein are the interventions with actual support behind them, and neither is sold in a vial.
Is tirzepatide worse than semaglutide for muscle?
A 2026 analysis of routine care data covered 670,422 people, with paired body composition measurements in 7,965 of them. It found greater lean mass loss on tirzepatide than on semaglutide at every time point measured.[^4]
A pattern they call the depletive metabotype, meaning more than 20% weight loss with more than 5% lean mass loss, occurred in 10.3% of tirzepatide users against 6.7% on semaglutide. In both groups, higher doses and longer exposure went with more lean loss.
This is a preprint and has not completed peer review. And it is observational, so the people prescribed each drug differ in ways that are hard to adjust for.
It matters because nothing else compares the two on this outcome at scale. Our three-way comparison covers how differently these drugs get discussed given how similar they appear.
Gallstones after rapid weight loss
The one genuine medical event on this page, and it gets almost no coverage relative to how often it happens.
Rapid weight loss supersaturates bile with cholesterol, which forms stones. GLP-1 drugs add a second mechanism by slowing gallbladder emptying directly.[^6] Two routes to the same place.
A pooled analysis of the placebo-controlled STEP trials found about 2.0 gallbladder events per 100 patient-years on semaglutide 2.4 mg, against 0.8 on placebo. That works out at roughly one additional event per 90 to 100 people treated for a year, and stones accounted for most of them.[^7]
The wider picture is worse. A meta-analysis of 76 randomised studies and over 103,000 patients found the risk higher with higher doses and longer duration. It was also markedly higher in weight loss populations than in diabetes populations.[^6] Losing more, faster, carries the most risk, which describes most people reading this.
The absolute risk stays low. What matters is recognising it, because gallbladder pain is easy to attribute to the drug's ordinary GI effects.
Upper right abdominal pain, particularly after eating and particularly if it radiates to the shoulder or back, is worth taking seriously rather than absorbing into the general nausea. Pain with fever or jaundice is urgent.
What can you take for loose skin?
The question asked most often and the one with the shortest answer.
No peptide, cream or supplement has been shown to tighten skin after major weight loss. Not collagen, not GHK-Cu, not BPC-157. The skincare peptides guide covers what the topical compounds can and cannot reach, and the answer is the outer layer of the epidermis rather than anything structural.
Skin does retract somewhat over twelve to eighteen months, more in younger people and in those who lost weight slowly. Beyond that, surgery is the only intervention that removes excess skin, which our guide on surgery covers from the anaesthetic side and which is worth reading if you are on a GLP-1 and considering it.
Anybody selling you a compound for loose skin is selling you something that has never been tested for it.
Why is my hair falling out after weight loss?
Thinning three to six months after rapid weight loss is common, distressing, and usually temporary.
It is typically telogen effluvium, where a physiological stress pushes a large number of hairs into the shedding phase at once.[^9] Rapid weight loss, reduced calorie intake and nutritional gaps all qualify as that kind of stress.
The trial numbers put it in proportion. In the Wegovy programme, hair loss was reported by 3.3% on semaglutide against 1.4% on placebo. And it tracked with how much weight came off: 5.3% of those losing more than 20% of their body weight reported it, against 2.5% of those losing less.[^9]
That last figure is the relevant one here, because losing more than 20% is the situation this page describes.
It generally recovers over six to nine months once the trigger settles, without treatment.
What is worth checking rather than assuming: iron, ferritin, thyroid function and protein intake. All four are common contributors, all are correctable, and our bloodwork guide covers how to approach that. Hair thinning that continues past a year, or that comes with a changing pattern rather than general thinning, is worth seeing somebody about.
What about bone density?
Weight loss by any route reduces bone mineral density, and the concern applies here for the same reason it applies to muscle: tissue comes off alongside the fat.
The evidence is thin to the point of being unhelpful. A 2025 post hoc analysis of a twenty-week pilot trial in twenty older adults found no significant difference in whole-body bone density or bone turnover markers between semaglutide and lifestyle counselling alone.[^8]
That is not reassurance. Twenty people over twenty weeks cannot detect a bone density change, which takes longer and larger numbers to measure. The authors also note the observed differences ran consistently toward lower density and higher turnover in the semaglutide group, without reaching significance.
So nobody has measured this properly, and the one attempt was too small to answer it.
If you are postmenopausal, over 65, or have a history of fracture, raise it with a doctor. A baseline DXA scan measures bone as well as body composition, and you may want both.
What is sold for this, and what it is worth
Three categories, and it is worth separating them.
The growth hormone secretagogues
Sold for muscle preservation. Our growth hormone roundup sets out what the trials found, and the pattern is a familiar one by now: body composition markers moved while function stayed put.
BPC-157 and the healing compounds
Sold for skin and recovery, with no completed human trial for anything.
The muscle-sparing drugs actually in development
A different thing entirely. Antibodies targeting activin and myostatin pathways are in real trials alongside GLP-1 drugs, specifically to preserve lean mass. None is a peptide and none is available, and between them they are the closest thing to a genuine pharmacological answer here.
That last category shows what a real intervention for this would look like, and what is being sold now is not it.
Weight loss drugs and disordered eating
Some of the advice above carries risk for some readers. Which advice, and why, is the subject of this section.
The people most drawn to these drugs skew vulnerable
Cross-sectional research found that greater interest in GLP-1s tracked with higher body dissatisfaction, higher body surveillance and shame, and stronger weight and shape concerns. Body appreciation and body neutrality went the other way, predicting less interest.
People with a history of eating disorders report greater interest in these drugs. Users of prescription weight loss medication show elevated eating disorder psychopathology.[^10]
That is a selection effect, not a claim about anyone in particular. It does mean a page about protein targets and measuring lean mass is being read by people for whom that framing is a problem.
Restriction looks identical to the drug working
On a drug that suppresses appetite, restriction looks identical to the medication working as intended. Eating very little is the expected effect.
A 2026 review drawing on bariatric surgery experience makes exactly this point. Telling pathological eating apart from expected medication-related change takes deliberate assessment. Without it, the two look the same from outside and often from inside.[^11]
Losing the weight does not update the internal picture
Body dissatisfaction and perceptual distortion frequently persist after substantial physical change. The pattern is sometimes described as phantom fat, where the internal model of body size resists updating.[^10]
So feeling roughly as you did before, after losing 30% of your body weight, is documented and not a failure of gratitude.
You can have a restrictive eating disorder at any weight
Atypical anorexia carries the symptoms of anorexia nervosa at average or above-average weight, including distorted body image and intense fear of weight gain. That group is both the most at risk of inappropriate prescribing and the least likely to be recognised.
If any of this is close to your situation, it is worth raising with somebody, and a doctor who prescribed the drug is a reasonable place to start. In the United States, the National Alliance for Eating Disorders runs a helpline staffed by licensed clinicians, and most countries have a national equivalent.
What happens if you stop taking it?
Relevant here because people reaching a goal weight often start asking about stopping.
In the STEP 1 extension, participants who had lost 17.3% regained 11.6 percentage points of it within a year of stopping, leaving a net loss of 5.6%. Cardiometabolic improvements largely reverted towards baseline.[^5]
That is not an argument for staying on it indefinitely, and it is information to have before deciding. Our guide on how long peptides take to work covers the same pattern in other compounds, and the decision belongs with a prescriber.
Can you lower the dose instead of stopping?
Everything above offers two choices, which is a false binary. Most people reaching a goal weight are asking about a third.
Maintenance dosing means continuing at a lower dose instead of the full weight-loss dose. It is common in practice, and the trial evidence for it is thinner than the evidence for either staying on the full dose or stopping entirely, which are the two arms trials tend to compare.
The regain data above comes from complete discontinuation, not from dose reduction, so it does not describe what happens on a lower dose. And appetite suppression is dose-related, which means a lower dose typically returns some appetite, which is the point and also the difficulty.
This is a prescriber conversation and a genuine one. It is also the decision point where our guide on running more than one peptide applies, because an open-ended protocol with no review date drifts by default.
What actually helps
Resistance training
The only intervention with real support for preserving lean mass during weight loss. Two or three sessions weekly, progressive load, and it matters more during the losing phase than after it.
Enough protein
Harder than it sounds when appetite is suppressed, which is the point of the drug. This is worth discussing with a dietitian if you are struggling, because it is a genuine conflict and not a willpower problem.
Measure something other than weight
A scale cannot tell you what came off. Grip strength, what you can lift, and how stairs feel all tell you more than the number does.
Patience with the skin
Twelve to eighteen months before assessing it, and a surgical consultation instead of a compound if it persists.
Where this stops being useful
What proportion of your own weight loss was lean tissue, which needs a DXA scan and not a bathroom scale.
Whether you should stop, continue or switch, which belongs with a prescriber.
Whether surgery is right for you, which is a consultation.
Common questions
Does semaglutide cause muscle loss?
Lean tissue accounted for somewhere between 30% and 40% of weight lost in the STEP 1 body composition substudy, though sources differ on the exact figure. Some lean loss happens in any weight loss. Physical function did not consistently decline in the STEP 1 analyses, and a 2026 study found grip strength going up.
How do I prevent muscle loss on a GLP-1?
Resistance training and adequate protein, which are the only interventions with real support. A case series found some people preserved or even increased lean tissue, with exercise the suggested explanation.
Is tirzepatide worse than semaglutide for muscle?
A 2026 analysis of routine care data found greater lean mass loss on tirzepatide at every time point. It is a preprint, it is observational, and it is the only large comparison of the two on this outcome.
What can I take for loose skin?
Nothing that has been shown to work. Skin retracts somewhat over twelve to eighteen months, and surgery is the only intervention that removes excess skin.
Why is my hair falling out?
Usually telogen effluvium from rapid weight loss, which typically recovers over six to nine months. Worth checking iron, ferritin, thyroid and protein intake, since all four are correctable contributors.
Will I regain the weight if I stop?
In the STEP 1 extension, people regained about two thirds of what they had lost within a year of stopping, and cardiometabolic improvements largely reverted.
I have lost the weight and I do not feel different. Is that normal?
It is documented. Body dissatisfaction and distorted perception frequently persist after substantial weight loss, a pattern sometimes called phantom fat, where the internal picture resists updating.
How do I tell restriction from the drug working?
That is genuinely difficult on a drug whose purpose is appetite suppression, and it is why clinicians are being advised to screen deliberately instead of waiting for it to be obvious. If the question has occurred to you, it is worth raising with somebody.
Can I lower the dose instead of stopping?
Maintenance dosing is common in practice and less studied than either staying on the full dose or stopping. The regain figures above come from complete discontinuation, so they do not describe what happens on a reduced dose.
Do peptides help preserve muscle?
The growth hormone compounds show the pattern that recurs across this whole category: markers move, function does not. The drugs actually being developed for muscle preservation alongside GLP-1s are antibodies, not peptides, and none is available.
Sources
[^1]: STEP 1 trial body composition substudy. Peer-reviewed randomised controlled trial substudy, reported across several secondary analyses. Participants on semaglutide 2.4 mg lost approximately 6.9 kg of lean soft tissue alongside 10.4 kg of fat mass. Published analyses give the lean proportion of total weight loss as approximately 30%, 34% and 40%, and this guide reports the range instead of selecting one figure. The substudy is variously described as n=95 and n=140, which likely reflects different analysis populations. Reported findings include an increased proportion of lean body mass relative to total body mass, and no consistent clinically meaningful declines in physical function. The primary STEP 1 publication and its DXA substudy should both be read at source before publication, and the discrepancy in the lean proportion resolved there.
[^2]: Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Peer-reviewed prospective study, abstract read at source. 115 patients enrolled, 106 completed, mean BMI 46.3, treated with semaglutide 2.4 mg. Weight loss 10% at seven months and 13% at twelve. Total fat mass fell 14% then 18%. Lean mass declined approximately 3 kg at seven months then stabilised. Handgrip strength improved by 4.5 kg at twelve months, and the prevalence of sarcopenic obesity fell from 49% at baseline to 33%. Note the high baseline BMI, which limits how far this generalises to people starting from a lower weight.
[^3]: Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. Peer-reviewed case series, abstract read at source. Three cases. One patient lost 8.7% of weight as lean soft tissue; two increased lean soft tissue. The authors state that lean soft tissue loss comprised 26% to 40% of weight loss in recent trials, and hypothesise that consistent exercise participation and resistance training contributed to the favourable outcomes observed. Three cases, and the causal claim is explicitly a hypothesis. Cited as an indication that the trial average is not fixed, and not as evidence of what preserves lean tissue.
[^4]: Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping. 2026. Preprint on medRxiv, not peer reviewed, abstract read at source. EHR-linked analysis of 670,422 first-episode GLP-1 users, 456,742 on semaglutide and 213,680 on tirzepatide, with 7,965 having paired pre- and post-initiation body composition measurements over twelve months. Excess lean body mass loss on tirzepatide of 1.1%, 1.5%, 1.3% and 2% at three, six, nine and twelve months. A depletive metabotype, defined as more than 20% total body weight loss with more than 5% lean body mass loss, occurred in 10.3% of tirzepatide users against 6.7% on semaglutide, p<0.001. Higher dose and longer exposure associated with greater decline in both, p<0.001. Observational and subject to confounding by indication; the preprint status is stated in the body text.
[^5]: Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Peer-reviewed trial extension, abstract read at source. 327 participants in the off-treatment extension. Mean weight loss from week 0 to 68 was 17.3% on semaglutide. Following withdrawal, participants regained 11.6 percentage points by week 120, leaving a net loss of 5.6%. Cardiometabolic improvements reverted towards baseline for most variables. All extension analyses were exploratory.
[^6]: GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications. Peer-reviewed review, read via search result. Records two mechanisms: rapid weight loss supersaturating bile with cholesterol, and direct GLP-1 mediated inhibition of gallbladder motility. Summarises He et al. 2022, a meta-analysis of 76 randomised trials and 103,371 patients, finding GLP-1 receptor agonists associated with increased risk of gallbladder and biliary disease at a relative risk of 1.37, with cholelithiasis at 1.27 and cholecystitis at 1.36. Risk was greater with higher doses, 1.56, longer duration, 1.40, and in weight loss trials at 2.29 compared with type 2 diabetes trials at 1.27. The He meta-analysis should be cited directly before publication, since the weight-loss-versus-diabetes contrast is the point the body text turns on.
[^7]: Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials. Peer-reviewed pooled analysis, abstract and conclusions read at source. Approximately 2.0 gallbladder events per 100 patient-years with semaglutide 2.4 mg against 0.8 per 100 patient-years with placebo across four trials, corresponding to roughly one additional gallbladder event per 90 to 100 treated patients over one year. Cholelithiasis accounted for the majority of events where individual diagnoses were reported. The authors describe the clinical implications as modest given the low absolute risk, while advising that patients be counselled about biliary symptoms particularly during the early phase of rapid weight loss.
[^8]: Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis. Frontiers in Aging, 2025. Peer-reviewed exploratory post hoc analysis, abstract read at source. Twenty older adults, mean age 72.7, randomised to semaglutide 1.0 mg weekly plus lifestyle counselling or lifestyle counselling alone for twenty weeks. No significant differences in whole-body bone mineral density, p=0.77, or in bone turnover markers CTX and P1NP. The authors note that observed differences showed consistently lower bone density and higher bone turnover in the semaglutide group, and state that additional work is warranted. Twenty participants over twenty weeks is far too small and too short to detect a bone density change, which is the point made in the body text; this is cited as an absence of evidence rather than evidence of absence.
[^9]: Telogen effluvium following rapid weight loss, and muscle-sparing agents in development. Telogen effluvium after rapid weight loss, caloric restriction or nutritional deficiency is well described in the dermatology literature, typically presenting three to six months after the trigger and resolving over six to nine months. A dermatology reference should be cited directly before publication. Trial figures are drawn from a 2025 analysis reporting Wegovy trial data of 3.3% hair loss against 1.4% on placebo, relative risk 2.38, 95% CI 1.41 to 4.0, and 5.3% alopecia among those losing more than 20% of body weight against 2.5% in those losing less. That source is a preprint and the underlying trial data should be confirmed against the Wegovy label or the STEP publications before publishing these figures. Separately, antibodies targeting activin and myostatin pathways are in development for lean mass preservation alongside GLP-1 therapy; these are biologics rather than peptides and none is approved. A trial registry entry or review should be cited for that claim.
[^10]: Body image in the age of GLP-1s: emerging questions for research and practice and Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes. Peer-reviewed reviews, abstracts and relevant sections read via search result. The first records that greater interest in GLP-1s was associated with higher BMI, greater body dissatisfaction, higher body surveillance and body shame, and stronger weight and shape concerns, while higher body appreciation and body neutrality were associated with less interest; that individuals with a history of eating disorders report greater interest in GLP-1 use; and that users of prescription weight loss medications show elevated eating disorder psychopathology. The second records that weight loss, including rapid weight loss, does not automatically resolve body dissatisfaction or perceptual distortion, and describes the persistence of internal body size models resistant to updating. Both are cross-sectional and non-clinical in the relevant parts, which limits causal interpretation, and this is stated in the body text as a selection effect rather than a claim about individuals. The underlying primary studies should be located before publication.
[^11]: Eating Disorder Risk and Screening in Patients Using GLP-1RAs: Lessons Learned From Metabolic and Bariatric Surgery. International Journal of Eating Disorders, 2026. Peer-reviewed review, abstract read via search result. States that the effects of GLP-1 receptor agonists on eating disorders remain largely unknown, that as with other medical weight loss interventions they may increase risk of eating disorder onset or exacerbation, that experience from metabolic and bariatric surgery supports routine screening before, during and after treatment, and that careful assessment is needed to distinguish pathological eating behaviours from expected medication-related changes. That last point is the basis for the detection problem described in the body text.